Small Molecule Protein-Protein Interaction Inhibitors
Stay tuned for a FREE webinar with an introduction to new developments in drug discovery where computational methods will play a bigger if not a dominant role in the early stages in drug development in the future.
Small Molecule Protein-Protein-interaction inhibitors (smPPII) are an emerging drug class which recently has entered the discussion of drug discovery and R&D productivity. By targeting “hot spots” on the protein surface, small molecules have shown to be able to disrupt effectively protein-protein interactions. This approach seem to decrease risks for later drug development stages.
Computational methods applied for the discovery and design of appropriate smPPII compounds have proven to deliver better quality in significant shorter time and substantial lower cost.
In combination, computational discovery and design methods and smPPIIs provide a double de-risk strategy in drug development and create a quantum leap in R&D productivity.
This webinar discusses our experience in this field and the implications on the early drug discovery phase in particular.